NASDAQ:NEO
Neogenomics Inc.
Neogenomics Inc.'s revenue grew 10.1% in fiscal 2025 to $727.3M while operating margin fell to −15.9%. Free cash flow was −$21.8M, −3.0% of revenue, and the diluted share count rose 1.1%.Summary generated from Neogenomics Inc.'s SEC filings. Latest annual report filed Feb 17, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)$727.3M
Revenue growth+10.1%
Revenue, 5-yr CAGR+10.4%
Gross margin43.2%
Operating margin−15.9%
Net margin−14.9%
ROIC−8.7%
Return on equity−12.4%
Debt / equity0.41
Free cash flow−$21.8M
FCF margin−3.0%
Share count change+1.1%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 484 | 510 | 592 | 661 | 727 |
| Operating income | −119 | −158 | −108 | −92 | −116 |
| Net income | −8 | −144 | −88 | −79 | −108 |
| Free cash flow | −91 | −97 | −31 | −34 | −22 |
Recent filings
- 4Insider transaction report
Oct 5, 2026 - 8-KResults of operations and financial condition
Oct 5, 2026 - 4Insider transaction report
Sep 3, 2026 - 8-KDirector or officer change
Aug 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 28, 2026 - 8-KResults of operations and financial condition
Jul 28, 2026 - 8-K/AAmended regulation FD disclosure
Jul 22, 2026 - 8-KRegulation FD disclosure
Jul 20, 2026